International Regulatory Endeavor towards Sound Development of Human Cell Therapy Products

February 18-19th, 2015
Hitotsubashi Hall, Tokyo, Japan

Organized by
International Alliance for Biological Standardization (IABS)

With the support from
Pharmaceuticals and Medical Devices Agency (PMDA)
Japan Science and Technology Agency (JST)
National Institute of Biomedical Innovation (NIBIO)
***
World Health Organization (WHO)

Under the auspices of
Ministry of Health, Labour and Welfare (MHLW): Pending (申請中)
Forum for Innovative Regenerative Medicine (FIRM)
Japan Pharmaceutical Manufacturers Association (JPMA)
The Japanese Society for Regenerative Medicine (JSRM)

Please visit the workshop website: http://www.iabs.org/

Registration fees

<table>
<thead>
<tr>
<th>Category</th>
<th>Early registration (before January 31, 2015)</th>
<th>Regular registration (February 1 - February 19, 2015)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IABS member, Government / Trainee / Student</td>
<td>US$ 80</td>
<td>US$ 120</td>
</tr>
<tr>
<td>Non-IABS member, Government / Trainee / Student</td>
<td>US$ 90</td>
<td>US$ 140</td>
</tr>
<tr>
<td>IABS member, Academia / Research Institute</td>
<td>US$ 250</td>
<td>US$ 300</td>
</tr>
<tr>
<td>Non-IABS member, Academia / Research Institute</td>
<td>US$ 300</td>
<td>US$ 350</td>
</tr>
<tr>
<td>Industry IABS member</td>
<td>US$ 400</td>
<td>US$ 500</td>
</tr>
<tr>
<td>Non-IABS member, Industry</td>
<td>US$ 500</td>
<td></td>
</tr>
</tbody>
</table>

AGENDA (Draft 5 JAN. 2015)

Day 1 – Wednesday, FEBRUARY 18, 2015
Session 1 Keynote Lecture
Session 2 Introduction of the meeting including the concept of a minimum consensus package plus case by case approaches for evaluating human cell therapy products (hCTPs)
Session 3 Specific points to consider for the evaluation and control of hCTPs that are different from those of traditional biological/biotechnological protein products (1)

Day 2 – Thursday, FEBRUARY 19, 2015
Session 4 Specific points to consider for the evaluation and control of hCTPs that are different from those of traditional biological/biotechnological protein products (2)
Session 5 Identification of specific points/issues for specific types of products, as well as very critical points/issues for various types of products (1)
Session 6 Identification of specific points/issues for specific types of products, as well as very critical points/issues for various types of products (2)